MannKind (MNKD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MNKD MannKind

Watchlist

6.850
-0.050-0.72%

Trading Nov 22 09:31 ET

1.89BMarket Cap85.63P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
MT NewswiresNov 14 12:56 ET · Ratings
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
Moomoo NewsNov 12 08:33 ET · Ratings
IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit
PR NewswireNov 11 09:14 ET
MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating
TipRanksNov 11 01:25 ET · Ratings
Q3 2024 MannKind Corp Earnings Call
Yahoo FinanceNov 8 13:26 ET
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
TipRanksNov 8 07:05 ET · Ratings

Comments

BelleWeather

3 hours ago

Housekeeping continued…

Surpassed target price and am focusing elsewhere.

Share Your Profit/Loss

BelleWeather

Oct 25 14:15

Scaling out

of LETFs and contracts…

Share Your Profit/Loss

BelleWeather

Oct 18 21:03

MannKind

I think this company still has room to grow and may be undervalued, however it is next to being scaling out for other opportunities as the space is crowded and many new therapies have advanced.

Share Your Profit/Loss

BelleWeather

Sep 23 16:26

Trading Plan on Shares

I think $United Natural Foods (UNFI.US)$
is still undervalued. Originally purchased as a longterm hold, I intend to sell instead at ~25 USD and put the capital toward other trades, likely CSPs focusing on other equities for longterm holds.
A speculative hold for the longterm, though may take profit if another opportunity beckons. This is the same approach as to $MannKind (MNKD.US)$ and $Iovance Biotherapeutics (IOVA.US)$ :
Two speculative positions that I am building (similar ...

Share Your Profit/Loss

BelleWeather

Sep 18 11:54

MannKind Calls

These calls performed well in theory, but I was unable to get a fill at maximum profit, which was about 90%. I’ve learned a realted lesson a few times. It’s key to trade options with a great deal of liquidity. (Or pay a fee for more obscure tickers, in order to get a more beneficial fill.) I now largely trade more popular contracts and use LEAPS to speculate in the longer term on less heavily traded equities; treating them as less capital intensive share proxies, to be traded at a ...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

MNKD MannKind

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target